BIO REFERENCE LABORATORIES INC Form 10-Q March 05, 2010

(Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.
	For the quarterly period ended January 31, 2010

• TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Or

For the transition period from

to

Commission File Number 0-15266

BIO-REFERENCE LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

NEW JERSEY

22-2405059

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

481 Edward H. Ross Drive, Elmwood Park, NJ

07407

(Address of principal executive offices)

(Zip Code)

(201) 791-2600

(Registrant s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated file in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated Filer x

Non-accelerated Filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of the issuer s common stock, as of the latest practicable date: 13,873,986 shares of Common Stock (\$.01 par value) at March 5, 2010.

BIO-REFERENCE LABORATORIES, INC.

FORM 10-Q

JANUARY 31, 2010

<u>INDEX</u>

	Page
PART I. FINANCIAL INFORMATION	
Item 1. Financial Statements Consolidated Balance Sheets as of January 31, 2010 (unaudited) and October 31, 2009	1
Consolidated Statements of Operations for the three months ended January 31, 2010 and January 31, 2009 (unaudited)	3
Consolidated Statements of Cash Flows for the three months ended January 31, 2010 and January 31,2009 (unaudited)	4
Notes to consolidated financial statements (unaudited)	6
Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3. Quantitative and Qualitative Disclosures About Market Risk	13
Item 4. Controls and Procedures	13
PART II. OTHER INFORMATION	
Item 6. Exhibits	14
Signatures	15
Certifications	16

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

PART I FINANCIAL INFORMATION

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands Except Per Share Data]

ASSETS

	January 31, 2010 (Unaudited)	October 31, 2009
CURRENT ASSETS:	4.5.00 <	4
Cash and Cash Equivalents	\$ 15,396	
Accounts Receivable - Net	110,485	104,995
Inventory	4,460	4,148
Other Current Assets	1,840	1,879
Deferred Tax Assets	14,008	12,456
TOTAL CURRENT ASSETS	146,189	140,473
PROPERTY AND EQUIPMENT - AT COST	52,909	53,645
<u>LESS</u> : Accumulated Depreciation	(23,355)	(25,885)
PROPERTY AND EQUIPMENT - NET	29,554	27,760
OTHER ASSETS:		
Deposits	674	630
Goodwill - Net	21,386	21,386
Intangible Assets - Net	4,310	4,588
Other Assets	1,423	1,373
Deferred Tax Assets	711	1,180
TOTAL OTHER ASSETS	28,504	29,157
TOTAL ASSETS	\$ 204,247	\$ 197,390

The Accompanying Notes are an Integral Part of These Financial Statements.

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands Except Per Share Data]

<u>LIABILITIES AND SHAREHOLDERS EQUIT</u>Y

	January 31, 2010 (Unaudited)	October 31, 2009
CURRENT LIABILITIES:		
Accounts Payable	\$ 27,418	\$ 30,570
Accrued Salaries and Commissions Payable	8,054	8,758
Accrued Taxes and Expenses	5,588	9,108
Revolving Note Payable - Bank	22,531	12,452
Current Maturities of Long-Term Debt	1,198	1,192
Capital Lease Obligations - Short-Term Portion	2,383	2,409
TOTAL CURRENT LIABILITIES	67,172	64,489
LONG-TERM LIABILITIES:		
Capital Lease Obligations - Long-Term Portion	3,690	3,843
Long Term Debt - Net of Current Portion	4,234	4,535
TOTAL LONG-TERM LIABILITIES	7,924	8,378
COMMITMENTS AND CONTINGENCIES		
SHAREHOLDERS EQUITY:		
Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None		
Issued		
Common Stock, \$0.01 Par Value;		
Authorized 35,000,000 shares:		
Issued and Outstanding 13,870,986 and 13,847,438 at January 31, 2010 and at October 31,		
2009, respectively	139	138